|Industry:||Drug Manufacturers - Major|
|Sanofi was incorporated under the laws of France in 1994. It is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company also discovers, develops and distributes therapeutic solutions. The Company is engaged in offering solutions across areas of core historical strength and multiple growth platforms. Within its Pharmaceuticals business, it focuses on various areas which include diabetes, rare diseases, oncology, and other flagship products in anti-thrombotics, cardiovascular, renal and biosurgery fields. The Company is facing competition from generics for several of its major products, in an environment subject to cost containment pressures from both third party payers and healthcare authorities. The manufacturing and research operations of the Company is subject to increasingly stringent health, safety and environmental (HSE) laws and regulations. The Company has core strengths in healthcare, with 7 growth platforms which includes diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Through the acquisition of Genzyme, the Company has strongly reinforced its footprint in rare diseases.|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.